company background image

23andMe Holding NasdaqGS:ME Stock Report

Last Price


Market Cap







18 Aug, 2022


Company Financials +
ME fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health6/6

ME Stock Overview

23andMe Holding Co. operates as a consumer genetics testing company.

23andMe Holding Co. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for 23andMe Holding
Historical stock prices
Current Share PriceUS$4.18
52 Week HighUS$13.68
52 Week LowUS$2.12
1 Month Change47.70%
3 Month Change45.14%
1 Year Change-47.95%
3 Year Changen/a
5 Year Changen/a
Change since IPO-57.35%

Recent News & Updates

Aug 19

23andMe drops 8% as CFO resigns

The shares of genetics test provider 23andMe Holding Co. (NASDAQ:ME) dropped ~8% in the pre-market trading Friday after the company announced the resignation of its Chief Financial Officer Steven Schoch, effective Sep. 01. Citing a letter from Mr. Schoch on Aug. 15, 23andMe (ME) said he would no longer serve as the company’s principal financial officer and accounting officer from next month. However, Schoch will continue to serve the firm until Sep. 30, during the transition of his responsibilities and duties. Following his resignation on Aug. 17, 23andMe's (ME) board of directors has approved the appointment of Joseph Selsavage as the company’s interim chief financial and accounting officer. Selsavage, who previously served as the CFO of Lemonaid Health, Inc., which was acquired by 23andMe (ME) in Nov. 2021, will serve as the company’s CFO on an interim basis pending an executive search for a permanent replacement. Mr. Schoch's departure comes in the wake of ME's Q2 2022 financials, which indicated an over two-fold sequential rise in the company's net loss.

Aug 11
23andMe Holding Co. (NASDAQ:ME) Just Reported, And Analysts Assigned A US$5.00 Price Target

23andMe Holding Co. (NASDAQ:ME) Just Reported, And Analysts Assigned A US$5.00 Price Target

Shareholders will be ecstatic, with their stake up 34% over the past week following 23andMe Holding Co. 's ( NASDAQ:ME...

Aug 07

23andMe Q1 2023 Earnings Preview

23andMe (NASDAQ:ME) is scheduled to announce Q1 earnings results on Monday, August 8th, after market close. The consensus EPS Estimate is -$0.16 (+36.0% Y/Y) and the consensus Revenue Estimate is $61.6M (+4.0% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward. Revenue estimates have seen 0 upward revisions and 1 downward.

Shareholder Returns

MEUS HealthcareUS Market

Return vs Industry: ME underperformed the US Healthcare industry which returned 13.8% over the past year.

Return vs Market: ME underperformed the US Market which returned -9% over the past year.

Price Volatility

Is ME's price volatile compared to industry and market?
ME volatility
ME Average Weekly Movement12.9%
Healthcare Industry Average Movement8.7%
Market Average Movement7.6%
10% most volatile stocks in US Market17.1%
10% least volatile stocks in US Market3.1%

Stable Share Price: ME is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: ME's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

2006n/aAnne Wojcicki

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit.

23andMe Holding Co. Fundamentals Summary

How do 23andMe Holding's earnings and revenue compare to its market cap?
ME fundamental statistics
Market CapUS$1.89b
Earnings (TTM)-US$265.00m
Revenue (TTM)US$277.17m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ME income statement (TTM)
Cost of RevenueUS$149.43m
Gross ProfitUS$127.74m
Other ExpensesUS$392.73m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-0.59
Gross Margin46.09%
Net Profit Margin-95.61%
Debt/Equity Ratio0%

How did ME perform over the long term?

See historical performance and comparison